SCHEMBL3155232

SCHEMBL3155232

NC(=O)CN1C[C@H](c2ccccc2)CC1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.67
TSHR P16473 2/20 0.61
HPGD P15428 2/20 0.61
SMN1; SMN2 Q16637 3/20 0.57
ALDH1A1 P00352 3/20 0.57
APEX1 P27695 1/20 0.55
BLM P54132 1/20 0.55
LMNA P02545 1/20 0.55
CHRM2 P08172 1/20 0.52
CHRM4 P08173 1/20 0.52
CHRM5 P08912 1/20 0.52
CHRM1 P11229 1/20 0.52
CHRM3 P20309 1/20 0.52
BRD4 O60885 3/20 0.51
SIGMAR1 Q99720 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
KDM4E B2RXH2 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1906215 1.00 TP53 (0.67) TP53TSHRHPGDSMN1; SMN2ALDH1A1
SCHEMBL563022 1.00 TP53 (0.67) TP53TSHRHPGDSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL32688158 0.98 TP53 (0.65) TP53TSHRHPGDSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL32688148 0.98 TP53 (0.65) TP53TSHRHPGDSMN1; SMN2ALDH1A1
SCHEMBL9850874 0.88 TP53 (0.70) TP53TSHRHPGDSMN1; SMN2ALDH1A1
SCHEMBL9821188 0.85 TP53 (0.67) TP53TSHRHPGDSMN1; SMN2ALDH1A1
SCHEMBL32688308 0.84 TP53 (0.74) TP53TSHRHPGDSMN1; SMN2ALDH1A1
SCHEMBL20573309 0.84 TP53 (0.74) TP53TSHRHPGDSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL32688612 0.83 TP53 (0.72) TP53TSHRHPGDSMN1; SMN2ALDH1A1
SCHEMBL11553488 0.81 LMNA (0.71) TP53TSHRHPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160250185-A1 PHARMACEUTICAL COMPOSITION FOR CONTROLLING BODY MASS GAIN COMPRISING S-PHENOTROPIL LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2016-09-01 US claimed
US-11465135-B2 Bifunctional chiral organocatalytic compound having excellent enantioselectivity, preparation method therefor, and method for producing non-natural gamma-amino acid from nitro compound by using same KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2022-10-11 US disclosed
US-20200406243-A1 BIFUNCTIONAL CHIRAL ORGANOCATALYTIC COMPOUND HAVING EXCELLENT ENANTIOSELECTIVITY, PREPARATION METHOD THEREFOR, AND METHOD FOR PRODUCING NON-NATURAL GAMMA-AMINO ACID FROM NITRO COMPOUND BY USING SAME KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2020-12-31 US disclosed
US-20200406243-A1 BIFUNCTIONAL CHIRAL ORGANOCATALYTIC COMPOUND HAVING EXCELLENT ENANTIOSELECTIVITY, PREPARATION METHOD THEREFOR, AND METHOD FOR PRODUCING NON-NATURAL GAMMA-AMINO ACID FROM NITRO COMPOUND BY USING SAME KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2020-12-31 US disclosed
EP-3142662-B1 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH ELEVATED INDUCIBLE NITRIC OXIDE SYNTHASE AKCIJU SABIEDRIBA OLAINFARM (LV) 2020-07-08 EP disclosed
US-20180064687-A1 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH ELEVATED INDUCIBLE NITRIC OXIDE SYNTHASE AKCIJU SABIEDRIBA "OLAINFARM" (LV) 2018-03-08 US disclosed
US-20160250185-A1 PHARMACEUTICAL COMPOSITION FOR CONTROLLING BODY MASS GAIN COMPRISING S-PHENOTROPIL LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2016-09-01 US disclosed
US-20160250185-A1 PHARMACEUTICAL COMPOSITION FOR CONTROLLING BODY MASS GAIN COMPRISING S-PHENOTROPIL LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2016-09-01 US disclosed
WO-2015060702-A8 PHARMACEUTICAL COMPOSITION FOR CONTROLLING BODY MASS GAIN COMPRISING S-PHENOTROPIL LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2016-07-07 WO disclosed
US-9382203-B2 N-carbamoylmethyl-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use Joint Stock Company (JSC) “OLAINFARM” (LV) 2016-07-05 US disclosed
US-20150216846-A1 N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use JOINT STOCK COMPANY (JSC) "OLAINFARM" (LV) 2015-08-06 US disclosed
WO-2015060702-A1 PHARMACEUTICAL COMPOSITION FOR CONTROLLING BODY MASS GAIN COMPRISING S-PHENOTROPIL LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2015-04-30 WO disclosed
US-20140315972-A1 RS)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide compound having modulatory activity with a commensurate effect, pharmaceutical substance (variants) and its application, composition (variants) thereof AKHAPKINA, VALENTINA IVANOVNA (RU) 2014-10-23 US disclosed
CN-103987386-A (RS) -2- (2-oxo-4-phenylpyrrolidin-1-yl) acetamide compounds with modulating activity with commensurate effects, pharmaceutical substances (variants) and uses thereof, compositions (variants) thereof AKHAPKINA VALENTINA IVANOVNA 2014-08-13 CN disclosed
EP-2762138-A1 PHARMACEUTICAL SUBSTANCE (VARIANTS) AND COMPOSITIONS BASED THEREON WHICH EXHIBIT MODULATORY ACTIVITY WITH A COMMENSURATE EFFECT Akhapkina, Valentina Ivanovna (RU) 2014-08-06 EP disclosed
EP-2013166-B1 N-CARBAMOYLMETHYL-4(R)-PHENYL-2-PYRROLIDINONE, METHOD OF ITS PREPARATION AND PHARMACEUTICAL USE AKCIJU SABIEDRIBA OLAINFARM (LV) 2010-03-10 EP disclosed
US-20100022784-A1 N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use Joint Stock Company "Olainfarm" (LV) 2010-01-28 US disclosed
US-20100022784-A1 N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use Joint Stock Company "Olainfarm" (LV) 2010-01-28 US disclosed
EP-2013166-A2 N-CARBAMOYLMETHYL-4(R)-PHENYL-2-PYRROLIDINONE, METHOD OF ITS PREPARATION AND PHARMACEUTICAL USE Akciju Sabiedriba "Olainfarm" (LV) 2009-01-14 EP disclosed
WO-2007104780-A2 N- CARBAMOYLMETHYL- 4- (R) -PHENYL-2-PYRR0LIDIN0NE, METHOD OF ITS PREPARATION AND PHARMACEUTICAL USE AKCIJU SABIEDRIBA 'OLAINFARM' (LV) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11465135-B2 Bifunctional chiral organocatalytic compound having excellent enantioselectivity, preparation method therefor, and method for producing non-natural gamma-amino acid from nitro compound by using same NOTUM, ALDH7A1, AADAT TP53 3270/4885TSHR 4266/4885HPGD 863/4885
US-20100022784-A1 N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use PRMT6, CPS1, JMJD6 TP53 3584/4885TSHR 1892/4885HPGD 1201/4885
US-20200406243-A1 BIFUNCTIONAL CHIRAL ORGANOCATALYTIC COMPOUND HAVING EXCELLENT ENANTIOSELECTIVITY, PREPARATION METHOD THEREFOR, AND METHOD FOR PRODUCING NON-NATURAL GAMMA-AMINO ACID FROM NITRO COMPOUND BY USING SAME NOTUM, ALDH7A1, AADAT TP53 3270/4885TSHR 4266/4885HPGD 863/4885
US-20180064687-A1 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH ELEVATED INDUCIBLE NITRIC OXIDE SYNTHASE ARG2, NOS2, NOS3 TP53 2065/4885TSHR 3378/4885HPGD 155/4885
US-20150216846-A1 N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use PRMT6, CPS1, JMJD6 TP53 3584/4885TSHR 1892/4885HPGD 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.